Commentary: SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China

Other authors

Institut Català de la Salut

[Di Cosimo S] Biomarker Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy. [Porcu L] Laboratory of Methodology for Clinical Research, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy. [Malfettone A] Medica Scientia Innovation Research (MedSIR), New Jersey, United States. [Cortés J] Medica Scientia Innovation Research (MedSIR), New Jersey, United States. Medica Scientia Innovation Research (MedSIR), Barcelona, Spain. IOB Institute of Oncology, Quiron Group, Madrid, Spain. IOB Institute of Oncology, Quiron Group, Barcelona, Spain. Vall d'Hebron Insititute of Oncology (VHIO), Barcelona, Spain. [Miceli R] Clinical Epidemiology and Trial Organization Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy

Vall d'Hebron Barcelona Hospital Campus

Publication date

2021-09-10T10:06:39Z

2021-09-10T10:06:39Z

2020-07-10



Abstract

COVID-19; Atenció al càncer; Orientació del pacient


COVID-19; Cuidado del cáncer; Orientación al paciente


COVID-19; Cancer care; Patient guidance


A Commentary on: SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China. By Yu, J., Ouyang, W., Chua, M. L. K., and Xie, C. (2020). JAMA Oncol. doi: 10.1001/jamaoncol.2020.0980:ca_ES

Document Type

Article


Published version

Language

English

Publisher

Frontiers Media

Related items

Frontiers in Oncology;10

https://doi.org/10.3389/fonc.2020.01223

Recommended citation

This citation was generated automatically.

Rights

Attribution 4.0 International

http://creativecommons.org/licenses/by/4.0/

This item appears in the following Collection(s)